| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
84.83(B) |
| Last
Volume: |
4,830,404 |
Avg
Vol: |
8,731,484 |
| 52
Week Range: |
$64.58 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
3 |
5 |
9 |
14 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2020-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
12,213 |
29,277 |
|
- |
|
| Oday Daniel Patrick |
Chairman & CEO |
• • – |
2020-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
19,204 |
19,204 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2020-01-03 |
4 |
AS |
$64.63 |
$190,659 |
D/D |
(2,950) |
17,064 |
|
19% |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2020-01-03 |
4 |
OE |
$24.30 |
$71,670 |
D/D |
2,950 |
20,014 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-12-03 |
4 |
AS |
$65.77 |
$388,043 |
D/D |
(5,900) |
17,064 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-12-03 |
4 |
OE |
$24.30 |
$143,341 |
D/D |
5,900 |
22,964 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2019-11-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,208) |
75,641 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-25 |
4 |
S |
$66.85 |
$1,002,809 |
D/D |
(15,000) |
17,064 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-25 |
4 |
OE |
$40.56 |
$608,400 |
D/D |
15,000 |
32,064 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-19 |
4 |
S |
$64.91 |
$649,062 |
D/D |
(10,000) |
17,064 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-19 |
4 |
OE |
$24.30 |
$242,950 |
D/D |
10,000 |
27,064 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-18 |
4 |
S |
$63.85 |
$638,500 |
D/D |
(10,000) |
17,064 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-18 |
4 |
OE |
$24.30 |
$242,950 |
D/D |
10,000 |
27,064 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
762 |
17,064 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2019-11-10 |
4 |
D |
$65.38 |
$34,063 |
D/D |
(521) |
5,539 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial Officer |
• • – |
2019-11-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,133 |
6,060 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-05 |
4 |
S |
$66.06 |
$138,404 |
D/D |
(2,095) |
17,826 |
|
- |
|
| Dickinson Andrew D |
EVP, Chief Financial OfficerOf |
• – – |
2019-11-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,927 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-01 |
4 |
S |
$64.52 |
$258,099 |
D/D |
(4,000) |
19,921 |
|
- |
|
| Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
• • – |
2019-11-01 |
4 |
OE |
$16.89 |
$40,536 |
D/D |
2,400 |
23,921 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-10-28 |
4 |
S |
$63.31 |
$359,412 |
D/D |
(5,677) |
21,521 |
|
- |
|
| Lofton Kevin E |
Director |
• • – |
2019-10-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,527 |
64,859 |
|
- |
|
| Wold Olsen Per |
Director |
• • – |
2019-08-28 |
4 |
S |
$63.91 |
$313,671 |
D/D |
(4,908) |
97,854 |
|
- |
|
| Wold Olsen Per |
Director |
• • – |
2019-08-28 |
4 |
OE |
$23.76 |
$116,590 |
D/D |
4,908 |
102,762 |
|
- |
|
| Pletcher Brett A |
EVP, Gen Counsel & Corp Sec |
• • – |
2019-08-19 |
4 |
S |
$64.35 |
$39,123 |
D/D |
(608) |
27,198 |
|
- |
|
1105 Records found
|
|
Page 15 of 45 |
|
|
0.85 (1.27%) 
